Skip to Content

Idamycin PFS (idarubicin) Disease Interactions

There are 6 disease interactions with Idamycin PFS (idarubicin):

Major

Antineoplastics (Includes Idamycin PFS) ↔ Infections

Severe Potential Hazard, High plausibility

Applies to: Infection - Bacterial/Fungal/Protozoal/Viral

Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression. The use of these drugs may be contraindicated in patients with known infectious diseases. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy. Close clinical monitoring of hematopoietic function is recommended.

References

  1. "Product Information. Novantrone (mitoxantrone)." Immunex Corporation, Seattle, WA.
  2. "Product Information. Fludara (fludarabine)." Berlex, Richmond, CA.
  3. "Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company, Indianapolis, IN.
  4. Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992): 1396-7
  5. "Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb, Princeton, NJ.
  6. "Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.
  7. "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.
  8. "Product Information. Doxil (doxorubicin liposomal)." Sequis Pharmaceuticals Inc, Menlo Park, CA.
  9. "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.
  10. "Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb, Princeton, NJ.
  11. Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992): 314-5
  12. "Product Information. Taxotere (docetaxel)." Rhone-Poulenc Rorer, Collegeville, PA.
  13. "Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn, Kalamazoo, MI.
  14. "Product Information. Tabloid (thioguanine)." Glaxo Wellcome, Research Triangle Park, NC.
  15. "Product Information. Platinol (cisplatin)." Bristol-Myers Squibb, Princeton, NJ.
  16. "Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome, Research Triangle Pk, NC.
  17. "Product Information. Methotrexate (methotrexate)." Lederle Laboratories, Wayne, NJ.
  18. "Product Information. Xeloda (capecitabine)." Roche Laboratories, Nutley, NJ.
  19. "Product Information. Nipent (pentostatin)." Parke-Davis, Morris Plains, NJ.
  20. "Product Information. DTIC-Dome (dacarbazine)." Bayer, West Haven, CT.
  21. Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991): 671
  22. "Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb, Princeton, NJ.
  23. "Product Information. Thiotepa (thiotepa)." Lederle Laboratories, Wayne, NJ.
  24. "Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn, Kalamazoo, MI.
  25. "Product Information. Alkeran Tablets (melphalan)." Glaxo Wellcome, Research Triangle Pk, NC.
  26. Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990): 833-4
  27. "Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn, Kalamazoo, MI.
  28. "Product Information. Hycamtin (topotecan)." SmithKline Beecham, Philadelphia, PA.
  29. Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994): 407-8
  30. "Product Information. Vepesid (etoposide)." Bristol-Myers Squibb, Princeton, NJ.
  31. "Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation, Eatontown, NJ.
View all 31 references
Major

Idarubicin (Includes Idamycin PFS) ↔ Heart Disease

Severe Potential Hazard, Moderate plausibility

Applies to: Heart Disease

Idarubicin can cause myocardial toxicity leading to congestive heart failure. Patients with preexisting heart disease or prior anthracycline therapy are at increased risk of congestive heart failure. Close clinical monitoring of cardiac function, such as an electrocardiogram and/or determination of left ventricular ejection fraction, prior to each course of therapy is recommended.

References

  1. Chan-Lam D, Copplestone JA, Prentice A, Price R, Johnson S, Phillips M "Idarubicin cardiotoxicity in acute myeloid leukaemia." Lancet 340 (1992): 185-6
  2. "Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn, Kalamazoo, MI.
  3. Bertelli G, Amoroso D, Pronzato P, Rosso R "Idarubicin: an evaluation of cardiac toxicity in 77 patients with solid tumors." Anticancer Res 8 (1988): 645-6
  4. Gillies H, Liang R, Rogers H, Harper P, Parapia L, Cox G, Johnson S "Phase II trial of idarubicin in patients with advanced lymphoma." Cancer Chemother Pharmacol 21 (1988): 261-4
  5. Villani F, Galimberti M, Comazzi R, Crippa F "Evaluation of cardiac toxicity of idarubicin (4- demethoxydaunorubicin)." Eur J Cancer Clin Oncol 25 (1989): 13-8
View all 5 references
Major

Idarubicin (Includes Idamycin PFS) ↔ Hepatic Dysfunction

Severe Potential Hazard, Moderate plausibility

Applies to: Liver Disease

Idarubicin undergoes extensive extrahepatic metabolism and is primarily eliminated by biliary excretion. The pharmacokinetic disposition of idarubicin has not been studied in leukemia patients with hepatic impairment. It is thought that the metabolism of idarubicin would be decreased in moderate to severe hepatic dysfunction and lead to increased systemic drug levels and toxicity. Therapy with idarubicin should be administered cautiously and dosage reduction considered in patients with compromised hepatic function. Idarubicin injection should not be administered if bilirubin level exceeds 5 mg %. Clinical monitoring of hepatic function is recommended prior to and during therapy.

References

  1. Daghestani AN, Arlin ZA, Leyland-Jones B, Gee TS, Kempin SJ, Mertelsmann R, Budman D, Schulman P, Baratz R, Williams L, et al "Phase I and II clinical and pharmacological study of 4- demethoxydaunorubicin (idarubicin) in adult patients with acute leukemia." Cancer Res 45 (1985): 1408-12
  2. Petti MC, Mandelli F "Idarubicin in acute leukemias: experience of the Italian Cooperative Group GIMEMA." Semin Oncol 16 (1 Suppl) (1989): 10-5
  3. Dodion P, Finet C, Crespeigne N, Beer M, Nicaise C, Rozencweig M, Kenis Y "Phase I study of oral idarubicin given with a weekly schedule." Invest New Drugs 4 (1986): 31-8
  4. Krarup-Hansen A, Andersen E, Elbaek K, Rasmussen SN, Dalmark M "Phase I study of 4-demethoxydaunorubicin by oral route in patients with advanced cancer." Acta Oncol 27 (1988): 521-5
  5. Chisesi T, Capnist G, de Dominicis E, Dini E "A phase II study of idarubicin (4-demethoxydaunorubicin) in advanced myeloma." Eur J Cancer Clin Oncol 24 (1988): 681-4
  6. Lowenthal RM, Chesterman CN, Griffiths JD, Manoharan A, Harris MG, Herrmann RP, Rooney KF, Rozenberg MC, Salem HH, Wolf MM, et al "Oral idarubicin as single-agent treatment of acute nonlymphocytic leukemia in poor-risk patients." Cancer Treat Rep 71 (1987): 1279-81
  7. "Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn, Kalamazoo, MI.
View all 7 references
Major

Idarubicin (Includes Idamycin PFS) ↔ Myelosuppression

Severe Potential Hazard, High plausibility

Applies to: Bone Marrow Depression/Low Blood Counts, Bleeding, Fever, Infection - Bacterial/Fungal/Protozoal/Viral

Idarubicin induces severe myelosuppression at therapeutic doses. Therapy with idarubicin should be withheld in patients whose bone marrow function is severely depressed by prior irradiation or chemotherapy or whose marrow function is recovering from previous cytotoxic therapy. If the need outweighs the risk, extreme caution should be exercised in administering idarubicin. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Close clinical monitory of hematopoietic function is recommended.

References

  1. Daghestani AN, Arlin ZA, Leyland-Jones B, Gee TS, Kempin SJ, Mertelsmann R, Budman D, Schulman P, Baratz R, Williams L, et al "Phase I and II clinical and pharmacological study of 4- demethoxydaunorubicin (idarubicin) in adult patients with acute leukemia." Cancer Res 45 (1985): 1408-12
  2. Gillies H, Liang R, Rogers H, Harper P, Parapia L, Cox G, Johnson S "Phase II trial of idarubicin in patients with advanced lymphoma." Cancer Chemother Pharmacol 21 (1988): 261-4
  3. Ganzina F, Pacciarini MA, Di Pietro N "Idarubicin (4-demethoxydaunorubicin). A preliminary overview of preclinical and clinical studies." Invest New Drugs 4 (1986): 85-105
  4. Petti MC, Mandelli F "Idarubicin in acute leukemias: experience of the Italian Cooperative Group GIMEMA." Semin Oncol 16 (1 Suppl) (1989): 10-5
  5. Case DC Jr, Gerber MC, Gams RA, Crawford J, Votaw ML, Higano CS, Pruitt BT, Gould J "Phase II study of intravenous idarubicin in unfavorable non-Hodgkin's lymphoma." Cancer Res 52 (1992): 3871-4
  6. Milroy R, Cummings J, Kaye SB, Banham SW "Phase II clinical and pharmacological study of oral 4- demethoxydaunorubicin in advanced non-pretreated small cell lung cancer." Cancer Chemother Pharmacol 20 (1987): 75-7
  7. Elbaek K, Ebbehoj E, Jakobsen A, Juul P, Rasmussen SN, Bastholt L, Dalmark M, Steiness E, Ebbehj E "Pharmacokinetics of oral idarubicin in breast cancer patients with reference to antitumor activity and side effects." Clin Pharmacol Ther 45 (1989): 627-34
  8. Krarup-Hansen A, Andersen E, Elbaek K, Rasmussen SN, Dalmark M "Phase I study of 4-demethoxydaunorubicin by oral route in patients with advanced cancer." Acta Oncol 27 (1988): 521-5
  9. van Eys J, Steuber P, Haggard ME, Sabio H, Duncan M "Trial of daunomycin in acute promyelocytic leukemia of childhood: a Southwest Oncology Group Study." Am J Pediatr Hematol Oncol 3 (1981): 301-3
  10. Chevallier B, Monnier A, Metz R, Namer M, Marty M, Roche H, Bastit P, Hurteloup P "Phase II study of oral idarubicin in elderly patients with advanced breast cancer." Am J Clin Oncol 13 (1990): 436-9
  11. "Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn, Kalamazoo, MI.
View all 11 references
Major

Idarubicin (Includes Idamycin PFS) ↔ Renal Dysfunction

Severe Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction

Impaired renal function can affect the disposition of idarubicin. Therapy with idarubicin should be administered cautiously and dosage modification considered in patients with compromised renal function. Clinical monitoring of renal function is recommended prior to and during therapy.

References

  1. "Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn, Kalamazoo, MI.
Moderate

Idarubicin (Includes Idamycin PFS) ↔ Hyperuricemia

Moderate Potential Hazard, Moderate plausibility

Applies to: Hyperuricemia Secondary to Chemotherapy

Treatment with idarubicin may cause hyperuricemia as a result of rapid lysis of tumor cells. Levels of serum uric acid should be monitored and appropriate therapy should be initiated before starting therapy.

Idamycin PFS (idarubicin) drug Interactions

There are 448 drug interactions with Idamycin PFS (idarubicin)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide